BRINGING NOVEL DRUGS FOR BRAIN DISEASES
Unlocking the Brain.
Advancing Precision Therapeutics.
Braindoot is building an integrated precision brain-targeting platform that combines AI/ML-enabled molecule
prioritization, proprietary linker chemistry, and human-derived BBB validation to develop brain-penetrant
small-molecule therapeutics for Brain cancers & CNS disorders.
San Francisco, CA
HEADQUARTERS
Founded by Entrepreneurs, Clinicians, Corporate Leaders, Pharma Executives in 2025
STAGE
CNS Diseases
FOCUS
ABOUT US
Vision & Mission
01
Vision
At Braindoot Lifesciences, we envision a future where glioblastoma and other central nervous system (CNS) malignancies are treatable diseases, significantly improving patient survival and quality of life. We are dedicated to pioneering brain-penetrant therapies that precisely target and overcome the challenges of the blood-brain barrier.
02
Mission
At Braindoot Lifesciences, our mission is to transform outcomes in glioblastoma and other CNS malignancies by developing brain-penetrant therapies that precisely cross the blood-brain barrier. Through innovative, novel target inhibitors and tissue-specific targeting platforms, we aim to redefine the standards of care and improve survival and quality of life for patients facing the most challenging brain cancers.
98%
of small-molecule drugs — and nearly all large-molecule biologics — fail to cross the blood-brain barrier.
MARKET
Redefining CNS disease treatment through precision-targeted small-molecule therapeutics. Our innovative approach maximizes CNS targeting while minimizing systemic exposure and off-target toxicity.
OUR PLATFORMS
Three integrated platforms, one translational engine.
Proven drugs, solved by precision brain targeting — from candidate selection through human-relevant validation.
BLiS
Novel linker platform to develop a library of tunable linkers.
DRiS
Utilizing AI enables faster identification of potential small-molecule drug candidates for novel targets
LTiS
Recapitulates the structural, molecular and functional properties, cellular complexity and transporter regulation of the human blood brain barrier